The SMN1 gene and its product, the SMN protein, are potential therapeutic targets for spinal muscular atrophy, and the dysregulation of snRNAs may serve as a potential biomarker [117]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.